Bendamustine plus rituximab in newly‐diagnosed Waldenström macroglobulinaemia patients. A study on behalf of the French Innovative Leukaemia Organization (FILO)
Open Access
- 12 December 2018
- journal article
- letter
- Published by Wiley in British Journal of Haematology
- Vol. 186 (1), 146-149
- https://doi.org/10.1111/bjh.15718
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s MacroglobulinemiaThe New England Journal of Medicine, 2018
- Bendamustine and rituximab (BR) versus dexamethasone, rituximab, and cyclophosphamide (DRC) in patients with Waldenström macroglobulinemiaAnnals of Hematology, 2018
- Bendamustine and rituximab combination is safe and effective as salvage regimen in Waldenström macroglobulinemiaLeukemia & Lymphoma, 2015
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialThe Lancet, 2013
- Bendamustine Therapy in Patients With Relapsed or Refractory Waldenström's MacroglobulinemiaClinical Lymphoma Myeloma and Leukemia, 2011
- International prognostic scoring system for Waldenström macroglobulinemiaBlood, 2009